Dealings in Clinigen shares are expected to commence on AIM at 8.00am on Tuesday 25 September 2012, under the ticker symbol CLIN





Clinigen is a rapidly-growing specialty pharmaceutical and services company, with one clear aim: to deliver the right drug to the right patient at the right time.




To achieve our aim, we have built a group of complementary businesses which can operate efficiently in a complex global regulatory environment and which can ensure that precious medicines are delivered securely and effectively, wherever they are needed. Through three businesses, Clinigen SP, Clinigen GAP, and Clinigen CTS, we acquire, license and revitalise niche, hospital-only critical care medicines, and source and supply our own and other pharmaceutical companies’ products, whether to meet unmet medical needs or for use in clinical trials.





Clinigen Clinical Trials Supply (CTS):

We use our global expertise, systems and relationships to source and manage the supply of commercial medicines to pharmaceutical companies for use exclusively in clinical trials. This requires excellent knowledge of the global pharmaceutical market, the regulatory processes and customs authorities of countries all over the world, along with a high tech supply chain with guaranteed quality and safety standards that can deliver swiftly.

Clinigen Global Access Programs (GAP):

On behalf of pharmaceutical and biotech companies, we manage essential programs that provide access to critical medicines for physicians and their patients all over the world. But what is a Global Access Program? Known by many terms from ‘expanded access’ and ‘named patient’ to ‘compassionate use’ and ‘early access’, a global access program enables physicians to access treatments that are not available in their own country for patients with an unmet medical need. Wherever they are, we can deliver treatments quickly, efficiently and, most importantly, ethically.

Clinigen Specialty Pharmaceuticals (SP):

We acquire niche medicines that don’t fit into the portfolio of larger pharmaceutical companies. These are typically hospital-only treatments for rare or life-threatening diseases, and we specialise in revitalising them – finding new treatment areas; new markets where we can get them licensed; or, potentially, new formulations. All the while, we’re ensuring that patients already using the medicine continue to get the treatment they need, while the company whose product we have acquired can feel confident that its reputation is being well looked after.

We are currently 100+ people, headquartered in Burton-on-Trent in the UK, with facilities in Philadelphia, US, and Tokyo, Japan, and an office in London. With a customer services team who speak over 19 languages between them, our clients from all over the world find us easy to do business with, while doctors and pharmacists find us a valuable source of information about how to access the medicines they need for their patients.




http://www.clinigen.co.uk/

Final Result
25 Sep 13 Clinigen Group [CLIN]

Preliminary Results

RNS


RNS Number : 8086O

Clinigen Group plc

25 September 2013












Clinigen Group plc

Preliminary Results for the year ended 30 June 2013

Burton-on-Trent, UK - 25 September 2013 - Clinigen Group plc ('Clinigen' or the 'Group') (AIM: CLIN), the global specialty pharmaceuticals business, has today published its preliminary results for the 12 months ended 30 June 2013.

Financial highlights

- Group revenue up by 49% to £122.6m (FY12: £82.1m) driven by strong organic growth across all three operational businesses

o Clinigen CTS full year sales up 49% to £87.8m and full year gross profit up 13% to £11.4m

o Clinigen GAP revenue grew more than six-fold to £10.5m; full year gross profit was up more than five-fold to £3.9m

o Clinigen SP full year sales of £24.3m (+12%) and full year gross profit of £19.8m (+8%)

- Underlying EBITDA increased by 30% to £22.4m (FY12: £17.3m)

- Underlying pre-tax profit increased by 29% to £20.4m (FY12: £15.8m) and reported pre-tax profits increased by 42% to £14.5m (FY12: £10.3m)

- Underlying earnings per share up 38% to 18.5 pence (FY12: 13.4 pence) and reported earnings per share 15.1 pence (FY12: 13.2 pence)

- Cash generation continues to be strong; cash and cash equivalents at 30 June 2013 were £11.3m, up from £5.2m at 30 June 2012

- Final dividend of 2.0 pence per share proposed, bringing the total dividend to 2.6 pence per share



Business highlights

- Clinical Trial Supply ("CTS")

o Sales performance driven by sizable anti-viral studies and increased activity in the US

o In June, extension of exclusive EU supply agreement with Accord Healthcare

- Global Access Programs ("GAP")

o Awarded Sanofi's Campath and Astellas' MDV3100 early access programs

o In July, BTG awarded a third access program to Clinigen and, in September, Eisai selected Clinigen to manage an access program in Germany

- Specialty Pharmaceuticals ("SP")

o Foscavir® sales volume continued to grow, with further expansion into the US and new indications in Europe

o Exclusive commercialization agreement in EU for Antibacterial, VIBATIV®

o Acquisition of oncology support therapy, Cardioxane® for US$33m





Peter George, Chief Executive Officer, said:



"We have over-delivered on our commitments made at the time of the IPO last September. In turn, the listing on AIM has lived up to our expectations. It has provided a stronger platform from which to drive our organic growth, both in the UK and internationally, as well as giving us additional financial flexibility to support our acquisition plans and the acceleration of our international growth strategy. The IPO has also enabled greater investment in the infrastructure and recruitment of additional high quality people to the business.



"Our ambition for the next financial year is to maintain this momentum across all three operating businesses; principally organic growth for CTS and GAP, and through further acquisition of products for SP. Geographically, we are focusing our attention on the US, Latin America and Asia.



"With a sound financial base, an increasing international footprint, as well as the recent organizational changes, we have the right foundations to continue the scale-up of the business and maintain our growth."



-Ends-

Clinigen: Investec places both its target price (prev.: 313p) and its hold recommendation unchanged


25 Sep Numis 485.00 Buy

City analysts hail Clinigen results
By Giles Gwinnett September 25 2013, 11:31am All three of the firm's divisions - Clinical Trial Supply (CTS), Global Access Programs (GAP) and Specialty Pharmaceuticals (SP) - saw an increase in sales or revenue.All three of the firm's divisions - Clinical Trial Supply (CTS), Global Access Programs (GAP) and Specialty Pharmaceuticals (SP) - saw an increase in sales or revenue.

---ADDS BROKER COMMENT AND SHARE PRICE---

Global pharma and services business Clinigen (LON:CLIN) posted full year results on Wednesday that beat analysts' forecasts.

The group unveiled a 49% increase in group revenues, driven by strong growth across all three of its operations.

In the year to end June, revenue stood at £122.6mln compared to £82.1 mln in 2012, while underlying pre-tax profit was up 29% to £20.4mln compared to £15.8mln last year.

Investors welcomed the numbers and Clinigen shares zoomed further upwards - 6.7% to 430p. The shares are now at an all time high and have doubled since the beginning of 2013.

The firm also ended the year in a good cash position, having £11.3mln - more than double the £5.2mln it had at June 20, 2012, and declared a final divi of 2p a share, making the total dividend for the year 2.6p a share.

All three of the firm's divisions - Clinical Trial Supply (CTS), Global Access Programs (GAP) and Specialty Pharmaceuticals (SP) - saw an increase in sales or revenue.

CTS, the largest contributor to sales, saw sales rise 49% to £87.8mln. This arm sources and supplies comparator drugs for use by big pharma and large research organisations when they are carrying out clinical trials.

GAP, whose revenue grew more than six-fold to £10.5mln, provides drugs that are still in trials but showing signs of efficacy.

SP, as the name suggests, is focused on acquiring medicines, developing and registering them before onward marketing. In the year, it saw sales increase 12%.

Broker Numis, which rates the shares a 'buy' targeting 485p, highlighted the firm's stated ambition to become the market leader in both CTS and GAP through organic growth, and to add a further 5-7 speciality pharmaceutical (SP) products over the next three to five years.

"If it accomplished this, we see over 100% upside to our 5-year earnings forecasts," says analyst Charles Weston.

As well as revenue and EBITDA beating forecasts, the broker said the full year dividend of 2.6p was considerably better than its 1.8p estimate, and net cash was £4mln better than expected, at £11mln.

Meanwhile, Investec said: "Clinigen’s preliminary results have come in ahead of our, and consensus, expectations in spite of 10% upgrades only two months ago."

The broker notes that although the share price has risen sharply in recent months, it believes the current ratings are "not a stretch given these results".

"We place our price target and recommendation under review,” it adds.

Earlier, the group's chief executive Peter George told investors: "We have over-delivered on our commitments made at the time of the IPO last September.

"In turn, the listing on AIM has lived up to our expectations. It has provided a stronger platform from which to drive our organic growth, both in the UK and internationally, as well as giving us additional financial flexibility to support our acquisition plans and the acceleration of our international growth strategy.

"The IPO has also enabled greater investment in the infrastructure and recruitment of additional high quality people to the business.

“Our ambition for the next financial year is to maintain this momentum across all three operating businesses; principally organic growth for CTS and GAP, and through further acquisition of products for SP. Geographically, we are focusing our attention on the US, Latin America and Asia.

“With a sound financial base, an increasing international footprint, as well as the recent organisational changes, we have the right foundations to continue the scale-up of the business and maintain our growth.”

Clinigen says momentum has carried into the new financial year
By Jeremy Naylor September 25 2013, 1:03pm

Well worth a watch.

http://www.proactiveinvestors.co.uk/companies/stocktube/2204/clinigen-says-momentum-has-carried-into-the-new-financial-year-2204.html

Thanks dreamcatcher

Pleased I can help

A buy in this weeks IC - Clinigen just the medicine.

Clinigen's share price has doubled since Jan 13 but rated on 16 times June 2015 earnings estimates, there should be more to come.

Clinigen directors to sell shares via placing
By Jamie Ashcroft September 30 2013, 5:16pm Books open on the placing right away and the pricing will be announced ‘as soon as practicable’ once the books close.Books open on the placing right away and the pricing will be announced ‘as soon as practicable’ once the books close.

Specialty pharmaceuticals firm Clinigen (LON:CLIN) announced on the AIM close that 10.6% of the group’s shares will be sold via a share placing.

Through the placing, which is being run by Numis and Peel Hunt, just over 8.7mln shares will be sold by the company’s directors.

Books open on the placing right away and the pricing will be announced ‘as soon as practicable’ once the books close.

It is planned that chief executive Peter George will sell just over 30% of his stake in the company, leaving him with a 7.3% shareholding (6mln shares).

Chief financial officer Robin Sibson and chief operating officer Shaun Chilton are also named as selling directors – each halving their stakes leaving them with 3% and 0.4% respectively.

Other un-named employees are also participating and those sales will account for around 3mln of the placing shares.

Last week Clinigen posted full year results that beat analyst forecasts.

It unveiled a 49% increase in group revenues, driven by strong growth across all three of its operations.

In the year to end June, revenue stood at £122.6mln compared to £82.1 mln in 2012, while underlying pre-tax profit was up 29% to £20.4mln compared to £15.8mln last year.

Clinigen placing completes at 410p per share
By John Harrington October 01 2013, 12:35pm Clinigen placing completes at 410p per share

Institutional investors have bought up just under 11% of the issued share capital of Clinigen (LON:CLIN) through a placing of shares at 410p each.

The shares have been sold by directors and employees of Clinigen at a 19.75p discount to the closing mid-market price on the day before the results of the share placing were announced.

Chief executive Peter George sold just over 30% of his stake in the company, leaving him with a 7.3% shareholding (6mln shares).

Chief financial officer Robin Sibson and chief operating officer Shaun Chilton both halved their stakes, leaving them with 3% and 0.4% respectively.

The directors have undertaken not to sell any more shares in the 180 days following the day the share placing was completed.

Last week Clinigen posted full year results that beat analyst forecasts.

It unveiled a 49% increase in group revenues, driven by strong growth across all three of its operations.

In the year to end June, revenue stood at £122.6mln compared to £82.1 mln in 2012, while underlying pre-tax profit was up 29% to £20.4mln compared to £15.8mln last year.

Clinigen CEO sells a further 0.5m shares post placing

Wed, 02 October 2013

Pharmaceuticals and services business Clinigen said Wednesday that Peter George, its Chief Executive Officer, has sold a further 0.5m shares in addition to the 2.8m disposed of on Monday.

The shares, which were all sold for 410p each, were part of the 8.7m placed with a number of directors on Monday.

George pocketed £2.050m from the most recent sale, and £11.6m from Monday's disposal.

The placing follows last week's full year results, which revealed a 49% jump in group revenue to £122.6m (FY12: £82.1m), which the firm said was driven by strong organic growth across all three operational businesses.

Underlying earnings before interest, tax, depreciation and amortisation (EBITDA) climbed 30% to £22.4m (FY12: £17.3m), while underlying pre-tax profit increased by 29% to £20.4m (FY12: £15.8m) and reported pre-tax profits increased by 42% to £14.5m (FY12: £10.3m).

Holding(s) in Company - Schroders plc gone above 10%

http://www.moneyam.com/action/news/showArticle?id=4681387

Clinigen Group PLC (CLIN:LSE) set a new 52-week high during today's trading session when it reached 494.25. Over this period, the share price is up 148.19%.

Clinigen: Investec increases target price from 313p to 469p reiterating its hold recommendation.

Flag on the chart showing stock is in consolidation phase. Reckon itl take off early november on a monday. Ill check my system and predict which monday. Bet I get it right.

Clinigen participating in the
BIO-Europe® Conference Vienna Nov 4-6




BIO-Europe® is Europe's largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. Produced with the support of BIO, it is regarded as a “must attend” event for the biotech industry

Then -



WODC Geneva

Geneva

14 November 2013 - 15 November 2013



ASH

New Orleans

5 December 2013 - 10 December 2013


http://www.ebdgroup.com/bioeurope/index.php

Interesting, watch out for my systems monday call. Not this monday.

In IC this week, one of thirteen red hot soaring shares.

With the consultancy business growing particularly strongly and new drugs on the roster for the coming year, there is a clear buzz about prospects.

Oh dear. Another one that has a huge sp.
BTW, didn't Directors do well to sell when it looked like a generous act....(recent News)...

Currently;- too high for me.

Even higher now, broken £5.